1
|
Liang Z, Yun CC. Compensatory Upregulation of LPA 2 and Activation of the PI3K-Akt Pathway Prevent LPA 5-Dependent Loss of Intestinal Epithelial Cells in Intestinal Organoids. Cells 2022; 11:2243. [PMID: 35883686 PMCID: PMC9324510 DOI: 10.3390/cells11142243] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Revised: 07/11/2022] [Accepted: 07/16/2022] [Indexed: 02/05/2023] Open
Abstract
Renewal of the intestinal epithelium is orchestrated by regenerative epithelial proliferation within crypts. Recent studies have shown that lysophosphatidic acid (LPA) can maintain intestinal epithelial renewal in vitro and conditional deletion of Lpar5 (Lpar5iKO) in mice ablates the intestinal epithelium and increases morbidity. In contrast, constitutive Lpar5 deletion (Lpar5cKO) does not cause a defect in intestinal crypt regeneration. In this study, we investigated whether another LPA receptor (LPAR) compensates for constitutive loss of LPA5 function to allow regeneration of intestinal epithelium. In Lpar5cKO intestinal epithelial cells (IECs), Lpar2 was upregulated and blocking LPA2 function reduced proliferation and increased apoptosis of Lpar5cKO IECs. Similar to Lpar5cKO mice, the absence of Lpar2 (Lpar2-/-) resulted in upregulation of Lpar5 in IECs, indicating that LPA2 and LPA5 reciprocally compensate for the loss of each other. Blocking LPA2 in Lpar5cKO enteroids reduced phosphorylation of Akt, indicating that LPA2 maintains the growth of Lpar5cKO enteroids through activation of the PI3K-Akt pathway. The present study provides evidence that loss of an LPAR can be compensated by another LPAR. This ability to compensate needs to be considered in studies aimed to define receptor functions or test the efficacy of a LPAR-targeting drug using genetically engineered animal models.
Collapse
Affiliation(s)
- Zhongxing Liang
- Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA;
| | - C. Chris Yun
- Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA;
- Gastroenterology Research, Atlanta Veterans Administration Medical Center, Decatur, GA 30322, USA
- Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
| |
Collapse
|
2
|
Chen L, Yan G, Ohwada T. Building on endogenous lipid mediators to design synthetic receptor ligands. Eur J Med Chem 2022; 231:114154. [DOI: 10.1016/j.ejmech.2022.114154] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 01/17/2022] [Accepted: 01/22/2022] [Indexed: 01/05/2023]
|
3
|
Liu W, Hopkins AM, Hou J. The development of modulators for lysophosphatidic acid receptors: A comprehensive review. Bioorg Chem 2021; 117:105386. [PMID: 34695732 DOI: 10.1016/j.bioorg.2021.105386] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2021] [Revised: 09/03/2021] [Accepted: 09/25/2021] [Indexed: 12/23/2022]
Abstract
Lysophosphatidic acids (LPAs) are bioactive phospholipids implicated in a wide range of cellular activities that regulate a diverse array of biological functions. They recognize two types of G protein-coupled receptors (LPARs): LPA1-3 receptors and LPA4-6 receptors that belong to the endothelial gene (EDG) family and non-endothelial gene family, respectively. In recent years, the LPA signaling pathway has captured an increasing amount of attention because of its involvement in various diseases, such as idiopathic pulmonary fibrosis, cancers, cardiovascular diseases and neuropathic pain, making it a promising target for drug development. While no drugs targeting LPARs have been approved by the FDA thus far, at least three antagonists have entered phase Ⅱ clinical trials for idiopathic pulmonary fibrosis (BMS-986020 and BMS-986278) and systemic sclerosis (SAR100842), and one radioligand (BMT-136088/18F-BMS-986327) has entered phase Ⅰ clinical trials for positron emission tomography (PET) imaging of idiopathic pulmonary fibrosis. This article provides an extensive review on the current status of ligand development targeting LPA receptors to modulate LPA signaling and their therapeutic potential in various diseases.
Collapse
Affiliation(s)
- Wenjie Liu
- Department of Chemistry, Lakehead University and Thunder Bay Regional Health Research Institute, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada
| | - Austin M Hopkins
- Department of Chemistry, Lakehead University and Thunder Bay Regional Health Research Institute, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada
| | - Jinqiang Hou
- Department of Chemistry, Lakehead University and Thunder Bay Regional Health Research Institute, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada.
| |
Collapse
|
4
|
Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special? Cells 2021; 10:cells10082059. [PMID: 34440828 PMCID: PMC8394178 DOI: 10.3390/cells10082059] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 08/06/2021] [Accepted: 08/07/2021] [Indexed: 12/13/2022] Open
Abstract
Lysophosphatidic acid (LPA) refers to a family of simple phospholipids that act as ligands for G protein-coupled receptors. While LPA exerts effects throughout the body in normal physiological circumstances, its pathological role in cancer is of great interest from a therapeutic viewpoint. The numerous LPA receptors (LPARs) are coupled to a variety of G proteins, and more than one LPAR is typically expressed on any given cell. While the individual receptors signal through conventional GPCR pathways, LPA is particularly efficacious in stimulating cancer cell proliferation and migration. This review addresses the mechanistic aspects underlying these pro-tumorigenic effects. We provide examples of LPA signaling responses in various types of cancers, with an emphasis on those where roles have been identified for specific LPARs. While providing an overview of LPAR signaling, these examples also reveal gaps in our knowledge regarding the mechanisms of LPA action at the receptor level. The current understanding of the LPAR structure and the roles of LPAR interactions with other receptors are discussed. Overall, LPARs provide insight into the potential molecular mechanisms that underlie the ability of individual GPCRs (or combinations of GPCRs) to elicit a unique spectrum of responses from their agonist ligands. Further knowledge of these mechanisms will inform drug discovery, since GPCRs are promising therapeutic targets for cancer.
Collapse
|
5
|
Solís KH, Romero-Ávila MT, Guzmán-Silva A, García-Sáinz JA. The LPA 3 Receptor: Regulation and Activation of Signaling Pathways. Int J Mol Sci 2021; 22:ijms22136704. [PMID: 34201414 PMCID: PMC8269014 DOI: 10.3390/ijms22136704] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Revised: 06/08/2021] [Accepted: 06/12/2021] [Indexed: 12/17/2022] Open
Abstract
The lysophosphatidic acid 3 receptor (LPA3) participates in different physiological actions and in the pathogenesis of many diseases through the activation of different signal pathways. Knowledge of the regulation of the function of the LPA3 receptor is a crucial element for defining its roles in health and disease. This review describes what is known about the signaling pathways activated in terms of its various actions. Next, we review knowledge on the structure of the LPA3 receptor, the domains found, and the roles that the latter might play in ligand recognition, signaling, and cellular localization. Currently, there is some information on the action of LPA3 in different cells and whole organisms, but very little is known about the regulation of its function. Areas in which there is a gap in our knowledge are indicated in order to further stimulate experimental work on this receptor and on other members of the LPA receptor family. We are convinced that knowledge on how this receptor is activated, the signaling pathways employed and how the receptor internalization and desensitization are controlled will help design new therapeutic interventions for treating diseases in which the LPA3 receptor is implicated.
Collapse
|
6
|
Meduri B, Pujar GV, Durai Ananda Kumar T, Akshatha HS, Sethu AK, Singh M, Kanagarla A, Mathew B. Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development. Eur J Med Chem 2021; 222:113574. [PMID: 34126459 DOI: 10.1016/j.ejmech.2021.113574] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 05/19/2021] [Accepted: 05/20/2021] [Indexed: 02/08/2023]
Abstract
Lysophosphatidic acid (LPA) activates six LPA receptors (LPAR1-6) and regulates various cellular activities such as cell proliferation, cytoprotection, and wound healing. Many studies elucidated the pathological outcomes of LPA are due to the alteration in signaling pathways, which include migration and invasion of cancer cells, fibrosis, atherosclerosis, and inflammation. Current pathophysiological research on LPA and its receptors provides a means that LPA receptors are new therapeutic targets for disorders associated with LPA. Various chemical modulators are developed and are under investigation to treat a wide range of pathological complications. This review summarizes the physiological and pathological roles of LPA signaling, development of various LPA modulators, their structural features, patents, and their clinical outcomes.
Collapse
Affiliation(s)
- Bhagyalalitha Meduri
- Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru, 570015 India
| | - Gurubasavaraj Veeranna Pujar
- Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru, 570015 India.
| | - T Durai Ananda Kumar
- Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru, 570015 India
| | - H S Akshatha
- Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru, 570015 India
| | - Arun Kumar Sethu
- Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru, 570015 India
| | - Manisha Singh
- Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Sri Shivarathreeshwara Nagara, Mysuru, 570015 India
| | - Abhinav Kanagarla
- Department of Pharmaceutical Chemistry, Andhra University, Visakhapatnam, Andhra Pradesh, 530003, India
| | - Bijo Mathew
- Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, India
| |
Collapse
|
7
|
Ueda N, Minami K, Ishimoto K, Tsujiuchi T. Effects of lysophosphatidic acid (LPA) receptor-2 (LPA 2) and LPA 3 on the regulation of chemoresistance to anticancer drug in lung cancer cells. Cell Signal 2020; 69:109551. [PMID: 32006610 DOI: 10.1016/j.cellsig.2020.109551] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2020] [Revised: 01/29/2020] [Accepted: 01/29/2020] [Indexed: 12/17/2022]
Abstract
Lysophosphatidic acid (LPA) mediates a variety of biological functions via the binding of G protein-coupled LPA receptors (LPA receptor-1 (LPA1) to LPA6). This study aimed to investigate the roles of LPA2 and LPA3 in the modulation of chemoresistance to anticancer drug in lung cancer A549 cells. In cell survival assay, cells were treated with cisplatin (CDDP) every 24 h for 2 days. The cell survival rate to CDDP of A549 cells was significantly elevated by an LPA2 agonist, GRI-977143. To evaluate the roles of LPA2-mediated signaling in cell survival during tumor progression, highly migratory (A549-R10) cells were generated from A549 cells. In the presence of GRI-977143, the cell survival rate to CDDP of A549-R10 cells were markedly higher than that of A549 cells, correlating with LPAR2 expression level. Moreover, to assess the effects of long-term anticancer drug treatment on cell survival, the long-term CDDP treated (A549-CDDP) cells were established from A549 cells. The cell survival rate to CDDP of A549-CDDP cells was elevated by GRI-977143. Since LPAR3 expression level was significantly higher in A549-CDDP cells than in A549 cells, we investigated the roles of LPA3 in the cell survival to CDDP of A549 cells, using an LPA3 agonist, 1-oleoyl-2-methyl-sn-glycero-3-phosphothionate ((2S)-OMPT). The cell survival rate to CDDP of A549 cells was significantly reduced by (2S)-OMPT treatment. In the presence of (2S)-OMPT, the cell survival rate to CDDP of A549 cells was elevated by LPA3 knockdown. These results suggest that LPA signaling via LPA2 and LPA3 is involved in the regulation of chemoresistance in A549 cells treated with CDDP.
Collapse
Affiliation(s)
- Nanami Ueda
- Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka 577-8502, Japan
| | - Kanako Minami
- Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka 577-8502, Japan
| | - Kaichi Ishimoto
- Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka 577-8502, Japan
| | - Toshifumi Tsujiuchi
- Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University, 3-4-1, Kowakae, Higashiosaka, Osaka 577-8502, Japan.
| |
Collapse
|
8
|
Ishimoto K, Minami K, Otagaki S, Tsujiuchi T. Rapid establishment of highly migratory cells from cancer cells for investigating cellular functions. J Recept Signal Transduct Res 2019; 39:194-198. [PMID: 31478788 DOI: 10.1080/10799893.2019.1638399] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Cell migration is closely involved in cancer cell invasion into surrounding tissue and metastasis to the distant organs. It is crucial for understanding the molecular mechanisms that regulate cell migration in cancer cells. The aim of this study is to establish a rapid induction method of highly migratory cells from cancer cells. Osteosarcoma MG-63 and colon cancer DLD1 cells were seeded at 1 × 105 cells in 6-well plates. After 10 min, unattached cells were washed off three times with PBS. The cells which remained attached on the bottom of plates were cultured in DMEM containing 10% FBS. When the cells reached approximately 80% confluence, cells were harvested using trypsin/EDTA. The harvested cells were seeded in other 6-well plates and incubated for 10 min. The unattached cells were washed off and attached cells were further cultured. By repeating this procedure 11-12 times for 2 months, highly migratory MG63-A12 and DLD-A11 cells were obtained from MG-63 and DLD1 cells, respectively. In cell motility assay, the cell motile activities of MG63-A12 and DLD-A11 cells was 10.3 and 13.7 times higher than those of the parental cells, respectively. This procedure is useful to generate highly migratory cells for investigating cellular functions during tumor progression in cancer cells.
Collapse
Affiliation(s)
- Kaichi Ishimoto
- Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University , Osaka , Japan
| | - Kanako Minami
- Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University , Osaka , Japan
| | - Shiho Otagaki
- Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University , Osaka , Japan
| | - Toshifumi Tsujiuchi
- Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kindai University , Osaka , Japan
| |
Collapse
|
9
|
Chabowski DS, Kadlec AO, Ait‐Aissa K, Hockenberry JC, Pearson PJ, Beyer AM, Gutterman DD. Lysophosphatidic acid acts on LPA 1 receptor to increase H 2 O 2 during flow-induced dilation in human adipose arterioles. Br J Pharmacol 2018; 175:4266-4280. [PMID: 30153326 PMCID: PMC6193883 DOI: 10.1111/bph.14492] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Revised: 07/23/2018] [Accepted: 08/09/2018] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND AND PURPOSE NO produces arteriolar flow-induced dilation (FID) in healthy subjects but is replaced by mitochondria-derived hydrogen peroxide (mtH2 O2 ) in patients with coronary artery disease (CAD). Lysophosphatidic acid (LPA) is elevated in patients with risk factors for CAD, but its functional effect in arterioles is unknown. We tested whether elevated LPA changes the mediator of FID from NO to mtH2 O2 in human visceral and subcutaneous adipose arterioles. EXPERIMENTAL APPROACH Arterioles were cannulated on glass micropipettes and pressurized to 60 mmHg. We recorded lumen diameter after graded increases in flow in the presence of either NOS inhibition (L-NAME) or H2 O2 scavenging (Peg-Cat) ± LPA (10 μM, 30 min), ±LPA1 /LPA3 receptor antagonist (Ki16425) or LPA2 receptor antagonist (H2L5186303). We analysed LPA receptor RNA and protein levels in human arterioles and human cultured endothelial cells. KEY RESULTS FID was inhibited by L-NAME but not Peg-Cat in untreated vessels. In vessels treated with LPA, FID was of similar magnitude but inhibited by Peg-Cat while L-NAME had no effect. Rotenone attenuated FID in vessels treated with LPA indicating mitochondria as a source of ROS. RNA transcripts from LPA1 and LPA2 but not LPA3 receptors were detected in arterioles. LPA1 but not LPA3 receptor protein was detected by Western blot. Pretreatment of vessels with an LPA1 /LPA3 , but not LPA2 , receptor antagonist prior to LPA preserved NO-mediated dilation. CONCLUSIONS AND IMPLICATIONS These findings suggest an LPA1 receptor-dependent pathway by which LPA increases arteriolar release of mtH2 O2 as a mediator of FMD.
Collapse
Affiliation(s)
- Dawid S Chabowski
- Department of Pharmacology and ToxicologyMedical College of WisconsinMilwaukeeWIUSA
| | - Andrew O Kadlec
- Department of PhysiologyMedical College of WisconsinMilwaukeeWIUSA
| | - Karima Ait‐Aissa
- Department of Medicine – Cardiovascular CenterMedical College of WisconsinMilwaukeeWIUSA
| | - Joseph C Hockenberry
- Department of Medicine – Cardiovascular CenterMedical College of WisconsinMilwaukeeWIUSA
| | - Paul J Pearson
- Department of Surgery – Cardiothoracic SurgeryMedical College of WisconsinMilwaukeeWIUSA
| | - Andreas M Beyer
- Department of PhysiologyMedical College of WisconsinMilwaukeeWIUSA
- Department of Medicine – Cardiovascular CenterMedical College of WisconsinMilwaukeeWIUSA
| | - David D Gutterman
- Department of Pharmacology and ToxicologyMedical College of WisconsinMilwaukeeWIUSA
- Department of PhysiologyMedical College of WisconsinMilwaukeeWIUSA
- Department of Medicine – Cardiovascular CenterMedical College of WisconsinMilwaukeeWIUSA
- VA Medical CenterMilwaukeeWIUSA
| |
Collapse
|
10
|
Lysophosphatidic acid receptor-2 (LPA 2) and LPA 5 regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells. Biochem Biophys Res Commun 2018; 503:2698-2703. [PMID: 30093116 DOI: 10.1016/j.bbrc.2018.08.026] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Accepted: 08/03/2018] [Indexed: 12/16/2022]
Abstract
Lysophosphatidic acid (LPA) receptors (LPA1 to LPA6) regulate a variety of malignant properties in cancer cells. In the present study, we investigated the roles of LPA receptors in the promotion of cellular functions during tumor progression in fibrosarcoma cells. To obtain long-term anticancer drug treated cells, human fibrosarcoma HT1080 cells were treated with methotrexate (MTX) and cisplatin (CDDP) for 6 months. LPAR2 and LPAR5 expressions were significantly higher in MTX-treated (HT-MTX) cells than in HT1080 cells. The cell motile and invasive activities of HT-MTX cells were significantly elevated compared with HT1080 cells. Although LPAR5 expression was increased in MTX and CDDP treated (HT-M-C) cells, no change of LPAR2 expression was observed. The cell motile and invasive activities of HT-M-C cells were lower than those of HT1080 cells. Moreover, to evaluate whether LPA receptors promote cell invasive activity, highly invasion (HT1080-M6) cells were established from HT1080 cells. The cell invasive activity of HT1080-M6 cells was approximately 4.5 times higher than HT1080 cell invasion. LPAR2 expression was markedly elevated in HT1080-M6 cells compared with HT1080 cells. The high cell invasion activity of HT1080-M6 cells was significantly suppressed by an antagonist of LPA2, H2L5186303. These results suggest that LPA2 acts as a key regulator of malignant properties in HT1080 cells.
Collapse
|
11
|
Llona-Minguez S, Ghassemian A, Helleday T. Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox. Prog Lipid Res 2015; 58:51-75. [DOI: 10.1016/j.plipres.2015.01.004] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2014] [Revised: 01/15/2015] [Accepted: 01/20/2015] [Indexed: 12/17/2022]
|
12
|
Abstract
Lysophosphatidic acid (LPA) and its receptors, LPA1-6, are integral parts of signaling pathways involved in cellular proliferation, migration and survival. These signaling pathways are of therapeutic interest for the treatment of multiple types of cancer and to reduce cancer metastasis and side effects. Validated therapeutic potential of key receptors, as well as recent structure-activity relationships yielding compounds with low nanomolar potencies are exciting recent advances in the field. Some compounds have proven efficacious in vivo against tumor proliferation and metastasis, bone cancer pain and the pulmonary fibrosis that can result as a side effect of pulmonary cancer radiation treatment. However, recent studies have identified that LPA contributes through multiple pathways to the development of chemotherapeutic resistance suggesting new applications for LPA antagonists in cancer treatment. This review summarizes the roles of LPA signaling in cancer pathophysiology and recent progress in the design and evaluation of LPA agonists and antagonists.
Collapse
|
13
|
The Src homology 3 binding domain is required for lysophosphatidic acid 3 receptor-mediated cellular viability in melanoma cells. Cancer Lett 2015; 356:589-96. [DOI: 10.1016/j.canlet.2014.10.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2014] [Revised: 09/29/2014] [Accepted: 10/03/2014] [Indexed: 12/29/2022]
|
14
|
Archbold JK, Martin JL, Sweet MJ. Towards selective lysophospholipid GPCR modulators. Trends Pharmacol Sci 2014; 35:219-26. [PMID: 24746475 DOI: 10.1016/j.tips.2014.03.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2013] [Revised: 03/13/2014] [Accepted: 03/14/2014] [Indexed: 01/08/2023]
Abstract
G-protein-coupled receptors (GPCRs) that recognize the lysophospholipids (LPLs) are grouped into two phylogenetically distinct families: the endothelial differentiation gene (Edg) and non-Edg GPCRs. Owing to their more recent identification, and hindered by a lack of selective pharmacological tools, our understanding of the functions and signaling pathways of the non-Edg GPCRs is still in its infancy. Targeting the non-conserved allosteric binding sites of the LPL GPCRs shows particular promise for the development of selective modulators by structure-based drug design. However, only one Edg GPCR (S1PR1) structure has been determined to date, and it has low sequence identity with the non-Edg GPCRs (<20%). Thus, a representative structure of a non-Edg GPCR remains a pressing objective for selective structure-based drug design. Obtaining selective modulators targeting the non-Edg receptors would help to unravel the biology behind these novel GPCRs and potentially will support therapeutic treatment of diseases such as cancer, inflammation, and neuropsychiatric disorders.
Collapse
Affiliation(s)
- Julia K Archbold
- Division of Chemistry and Structural Biology, The University of Queensland, Institute for Molecular Bioscience, St Lucia, Brisbane, QLD 4072, Australia.
| | - Jennifer L Martin
- Division of Chemistry and Structural Biology, The University of Queensland, Institute for Molecular Bioscience, St Lucia, Brisbane, QLD 4072, Australia
| | - Matthew J Sweet
- Division of Molecular and Cell Biology, The University of Queensland, Institute for Molecular Bioscience, St Lucia, Brisbane, QLD 4072, Australia
| |
Collapse
|
15
|
Development of lysophosphatidic acid pathway modulators as therapies for fibrosis. Future Med Chem 2013; 5:1935-52. [DOI: 10.4155/fmc.13.154] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Lysophosphatidic acid (LPA) is a class of bioactive phospholipid that displays a wide range of cellular effects via LPA receptors, of which six have been identified (LPAR1–6). In serum and plasma, LPA production occurs mainly by the hydrolysis of lysophosphatidylcholine by the phospholipase D activity of autotaxin (ATX). The involvement of the LPA pathway in driving chronic wound-healing conditions, such as idiopathic pulmonary fibrosis, has suggested targets in this pathway could provide potential therapeutic approaches. Mice with LPAR1 knockout or tissue-specific ATX deletion have demonstrated reduced lung fibrosis following bleomycin challenge. Therefore, strategies aimed at antagonizing LPA receptors or inhibiting ATX have gained considerable attention. This Review will summarize the current status of identifying small-molecule modulators of the LPA pathway. The therapeutic utility of LPA modulators for the treatment of fibrotic diseases will soon be revealed as clinical trials are already in progress in this area.
Collapse
|
16
|
Structural Characterization of an LPA1 Second Extracellular Loop Mimetic with a Self-Assembling Coiled-Coil Folding Constraint. Int J Mol Sci 2013; 14:2788-807. [PMID: 23434648 PMCID: PMC3588015 DOI: 10.3390/ijms14022788] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2012] [Revised: 11/16/2012] [Accepted: 01/24/2013] [Indexed: 12/16/2022] Open
Abstract
G protein-coupled receptor (GPCR) structures are of interest as a means to understand biological signal transduction and as tools for therapeutic discovery. The growing number of GPCR crystal structures demonstrates that the extracellular loops (EL) connecting the membrane-spanning helices show tremendous structural variability relative to the more structurally-conserved seven transmembrane α-helical domains. The EL of the LPA(1) receptor have not yet been conclusively resolved, and bear limited sequence identity to known structures. This study involved development of a peptide to characterize the intrinsic structure of the LPA(1) GPCR second EL. The loop was embedded between two helices that assemble into a coiled-coil, which served as a receptor-mimetic folding constraint (LPA(1)-CC-EL2 peptide). The ensemble of structures from multi-dimensional NMR experiments demonstrated that a robust coiled-coil formed without noticeable deformation due to the EL2 sequence. In contrast, the EL2 sequence showed well-defined structure only near its C-terminal residues. The NMR ensemble was combined with a computational model of the LPA(1) receptor that had previously been validated. The resulting hybrid models were evaluated using docking. Nine different hybrid models interacted with LPA 18:1 as expected, based on prior mutagenesis studies, and one was additionally consistent with antagonist affinity trends.
Collapse
|
17
|
Qian Y, Hamilton M, Sidduri A, Gabriel S, Ren Y, Peng R, Kondru R, Narayanan A, Truitt T, Hamid R, Chen Y, Zhang L, Fretland AJ, Sanchez RA, Chang KC, Lucas M, Schoenfeld RC, Laine D, Fuentes ME, Stevenson CS, Budd DC. Discovery of Highly Selective and Orally Active Lysophosphatidic Acid Receptor-1 Antagonists with Potent Activity on Human Lung Fibroblasts. J Med Chem 2012; 55:7920-39. [DOI: 10.1021/jm301022v] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Yimin Qian
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Matthew Hamilton
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Achyutharao Sidduri
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Stephen Gabriel
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Yonglin Ren
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Ruoqi Peng
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Rama Kondru
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Arjun Narayanan
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Terry Truitt
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Rachid Hamid
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Yun Chen
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Lin Zhang
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Adrian J. Fretland
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Ruben Alvarez Sanchez
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Kung-Ching Chang
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Matthew Lucas
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Ryan C. Schoenfeld
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Dramane Laine
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Maria E. Fuentes
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Christopher S. Stevenson
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - David C. Budd
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| |
Collapse
|
18
|
Abstract
Comparative modeling is a powerful technique to generate models of proteins from families already represented by members with experimentally characterized three-dimensional structures. The method is particularly important for modeling membrane-bound receptors in the G Protein-Coupled Receptor (GPCR) family, such as many of the lipid receptors (such as the cannabinoid, prostanoid, lysophosphatidic acid, sphingosine 1-phosphate, and eicosanoid receptor family members), as these represent particularly challenging targets for experimental structural characterization methods. Although challenging modeling targets, these receptors have been linked to therapeutic indications that vary from nociception to cancer, and thus are of interest as therapeutic targets. Accurate models of lipid receptors are therefore valuable tools in the drug discovery and optimization phases of therapeutic development. This chapter describes the construction and evaluation of comparative structural models of lipid receptors beginning with the selection of template structures.
Collapse
Affiliation(s)
- Abby L Parrill
- Department of Chemistry, The University of Memphis, Memphis, TN, USA.
| |
Collapse
|
19
|
Herr DR. Potential use of G protein-coupled receptor-blocking monoclonal antibodies as therapeutic agents for cancers. INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY 2012; 297:45-81. [PMID: 22608557 DOI: 10.1016/b978-0-12-394308-8.00002-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The therapeutic use of monoclonal antibodies (mAbs) is the fastest growing area of pharmaceutical development and has enjoyed significant clinical success since approval of the first mAb drug in1984. However, despite significant effort, there are still no approved therapeutic mAbs directed against the largest and most attractive family of drug targets: G protein-coupled receptors (GPCRs). GPCRs regulate essentially all cellular processes, including those that are fundamental to cancer pathology, such as proliferation, survival/drug resistance, migration, differentiation, tissue invasion, and angiogenesis. Many different GPCR isoforms are enhanced or dysregulated in multiple tumor types, and several GPCRs have known oncogenic activity. With approximately 350 distinct GPCRs in the genome, these receptors provide a rich landscape for the design of effective, targeted therapies for cancer, a uniquely heterogeneous disease family. While the generation of selective, efficacious mAbs has been problematic for these structurally complex integral membrane proteins, progress in the development of immunotherapeutics has been made by several independent groups. This chapter provides an overview of the roles of GPCRs in cancer and describes the current state of the art of GPCR-targeted mAb drugs.
Collapse
Affiliation(s)
- Deron R Herr
- Expression Drug Designs, LLC, San Marcos, California, USA
| |
Collapse
|
20
|
Rancoule C, Pradère JP, Gonzalez J, Klein J, Valet P, Bascands JL, Schanstra JP, Saulnier-Blache JS. Lysophosphatidic acid-1-receptor targeting agents for fibrosis. Expert Opin Investig Drugs 2011; 20:657-67. [DOI: 10.1517/13543784.2011.566864] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
21
|
Im DS. Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol Sin 2010; 31:1213-22. [PMID: 20729877 DOI: 10.1038/aps.2010.135] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Previous studies on lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) using various approaches have shown that both the molecules can act as intercellular signaling molecules. The discovery of the Edg subfamily of G-protein-coupled receptors (GPCRs) (later renamed LPA(1-3) and S1P(1-5)) for these molecules has opened up a new avenue for pathophysiological research on lysophospholipids. Genetic and molecular studies on lysophospholipid GPCRs have elucidated pathophysiological impacts and roles in cellular signaling pathways. Recently, lysophospholipid GPCR genes have been used to develop receptor subtype-selective agonists and antagonists. The discovery of FTY720, a novel immune modulator, along with other chemical tools, has provided a means of elucidating the functions of each lysophospholipid GPCR on an organ and the whole body level. This communication attempts to retrospectively review the development of agonists and antagonists for lysophospholipid GPCRs, provide integrated information on pharmacological tools for lysophospholipid GPCR signaling, and speculate on future drug development.
Collapse
|
22
|
Tigyi G. Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 2010; 161:241-70. [PMID: 20735414 PMCID: PMC2989581 DOI: 10.1111/j.1476-5381.2010.00815.x] [Citation(s) in RCA: 137] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2009] [Revised: 02/12/2010] [Accepted: 03/20/2010] [Indexed: 12/22/2022] Open
Abstract
Lysophosphatidic acid (LPA, 1-radyl-2-hydroxy-sn-glycero-3-phosphate) is the prototype member of a family of lipid mediators and second messengers. LPA and its naturally occurring analogues interact with G protein-coupled receptors on the cell surface and a nuclear hormone receptor within the cell. In addition, there are several enzymes that utilize LPA as a substrate or generate it as a product and are under its regulatory control. LPA is present in biological fluids, and attempts have been made to link changes in its concentration and molecular composition to specific disease conditions. Through their many targets, members of the LPA family regulate cell survival, apoptosis, motility, shape, differentiation, gene transcription, malignant transformation and more. The present review depicts arbitrary aspects of the physiological and pathophysiological actions of LPA and attempts to link them with select targets. Many of us are now convinced that therapies targeting LPA biosynthesis and signalling are feasible for the treatment of devastating human diseases such as cancer, fibrosis and degenerative conditions. However, successful targeting of the pathways associated with this pleiotropic lipid will depend on the future development of as yet undeveloped pharmacons.
Collapse
Affiliation(s)
- Gabor Tigyi
- Department of Physiology, University of Tennessee Health Science Center, Memphis, TN, USA.
| |
Collapse
|
23
|
Muddassar M, Jang JW, Hong SK, Cho YS, Kim EE, Keum KC, Oh T, Cho SN, Pae AN. Identification of novel antitubercular compounds through hybrid virtual screening approach. Bioorg Med Chem 2010; 18:6914-21. [PMID: 20727773 DOI: 10.1016/j.bmc.2010.07.010] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2010] [Revised: 07/02/2010] [Accepted: 07/03/2010] [Indexed: 11/17/2022]
Abstract
Growing resistance of prevalent antitubercular (antiTB) agents in clinical isolates of Mycobacterium tuberculosis (MTB) provoked an urgent need to discover novel antiTB agents. Enoyl acyl carrier protein (ACP) reductase (InhA) from Mtb is a well known and thoroughly studied as antitubucular therapy target. Here we have reported the discovery of potent antiTB agents through ligand and structure based approaches using computational tools. Initially compounds with more than 0.500 Tanimoto similarity coefficient index using functional class fingerprints (FCFP_4) to the reference chemotype were mined from the chemdiv database. Further, the molecular docking was performed to select the compounds on the basis of their binding energies, binding modes, and tendencies to form reasonable interactions with InhA (PDB ID=2NSD) protein. Eighty compounds were evaluated for antitubercular activity against H37RV M. tuberculosis strain, out of which one compound showed MIC of 5.70 microM and another showed MIC of 13.85 microM. We believe that these two new scaffolds might be the good starting point from hit to lead optimization for new antitubercular agents.
Collapse
Affiliation(s)
- Muhammad Muddassar
- Center for Chemoinformatics Research, Life Sciences Division, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Fells JI, Tsukahara R, Liu J, Tigyi G, Parrill AL. 2D binary QSAR modeling of LPA3 receptor antagonism. J Mol Graph Model 2010; 28:828-33. [PMID: 20356772 DOI: 10.1016/j.jmgm.2010.03.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2009] [Revised: 02/26/2010] [Accepted: 03/02/2010] [Indexed: 11/13/2022]
Abstract
A structurally diverse dataset of 119 compounds was used to develop and validate a 2D binary QSAR model for the LPA(3) receptor. The binary QSAR model was generated using an activity threshold of greater than 15% inhibition at 10 microM. The overall accuracy of the model on the training set was 82%. It had accuracies of 55% for active and 91% for inactive compounds, respectively. The model was validated using an external test set of 10 compounds. The accuracy on the external test set was 60% overall, identifying three out of seven actives and all three inactive compounds. This model was combined with similarity searching to rapidly screen libraries and select 14 candidate LPA(3) antagonists. Experimental assays confirmed 13 of these (93%) met the 15% inhibition threshold defining actives. The successful application of the model to select candidates for screening demonstrates the power of this binary QSAR model to prioritize compound selection for experimental consideration.
Collapse
Affiliation(s)
- James I Fells
- Department of Chemistry and Computational Research on Materials Institute, The University of Memphis, Memphis, TN 38152, United States
| | | | | | | | | |
Collapse
|